B

BeiGene Ltd

D
BGNE
USD
1.56
(0.791%)
Market Closed
6,639.00
Volume
-5.76004
EPS
-
Div Yield
-40.236842
P/E
21,084,802,251.37
Market Cap
Today
0.7910%
1 Week
1.248%
1 Month
3.241%
6 Months
18.168%
12 Months
-4.740%
Year To Date
10.171%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
E
EDIT
0.05
(1.292%)
USD
C
CRSP
-0.11
(-0.2219%)
USD
N
NVTA
(%)
USD
A
ARCT
0.49
(2.3833%)
USD
REGN
REGN
11.33
(0.9948%)
USD
MRNA
MRNA
-1.79
(-2.5637%)
USD
C
CRIS
-0.15
(-2.5084%)
USD
T
TBIO
1.57
(115.4412%)
USD
GILD
GILD
0.015
(0.0179%)
USD
I
INCY
1.67
(2.5625%)
USD

Title:
BeiGene Ltd

Sector:
Healthcare
Industry:
Biotechnology
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Do you need help or have a question?
Contact Us